Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS

(ALXN)
  Report  
Delayed Quote. Delayed Nasdaq - 09/17 04:00:00 pm
107.83 USD   -0.65%
09/17ALEXION PHARMACEUTICALS : Names New Finance Chief
DJ
09/17ALEXION PHARMACEUTICALS : Announces CFO Succession
BU
09/10Bridgebio Grants Japanese Rights to Eidos' ag10 to Alexion
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Alexion Up Nearly 8%, on Pace for Largest Percent Increase Since April 2018 -- Data Talk

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2019 | 03:54pm EDT

Alexion Pharmaceuticals, Inc. (ALXN) is currently at $123.73, up $8.89, or 7.74%

-- Would be highest close since July 10 when it closed at $124.37

-- On pace for largest percent increase since April 26, 2018, when it rose 14.5%

-- Earlier Thursday, Spanish business news website Intereconomia reported that Amgen Inc. is poised to buy Alexion Pharmaceuticals Inc. for about $45 billion, renewing speculation on a potential deal that has been rumored for more than a year

-- Currently up five of the past six days

-- Currently up two consecutive days; up 11.04% over this period

-- Best two-day stretch since the two days ending April 27, 2018, when it rose 14.46%

-- Up 9.22% month-to-date

-- Up 27.09% year-to-date

-- Down 40.47% from its all-time closing high of $207.84 on July 23, 2015

-- Traded as high as $125.52; highest intraday level since July 10 when it hit $127.74

-- Up 9.3% at Thursday's intraday high; largest intraday percent increase since April 26, 2018, when it rose as much as 16.24%

-- Third-best performer in the S&P 500 Thursday

-- Best performer in the Nasdaq 100 Thursday

All data as of 3:25 p.m. EDT

Source: Dow Jones Market Data, FactSet

Stocks mentioned in the article
ChangeLast1st jan.
ALEXION PHARMACEUTICALS -0.65% 107.83 Delayed Quote.11.48%
AMGEN 1.36% 196.72 Delayed Quote.1.05%
DJ INDUSTRIAL 0.13% 27110.8 Delayed Quote.16.07%
NASDAQ 100 0.46% 7888.7863 Delayed Quote.24.69%
NASDAQ COMP. 0.40% 8186.016151 Delayed Quote.23.23%
S&P 500 0.26% 3005.7 Delayed Quote.19.90%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALEXION PHARMACEUTICALS
09/17ALEXION PHARMACEUTICALS : Names New Finance Chief
DJ
09/17ALEXION PHARMACEUTICALS : Announces CFO Succession
BU
09/10Bridgebio Grants Japanese Rights to Eidos' ag10 to Alexion
AQ
09/09ALEXION : and BridgeBio Announce Japanese License Agreement for Eidos' Transthyr..
BU
09/05ALEXION PHARMACEUTICALS : Pharma Shares Fall After EU Patent Decision
DJ
09/04ALEXION PHARMACEUTICALS : to Present at the 17th Annual Morgan Stanley Global He..
BU
09/03Stocks to Watch: Alphabet, H&R Block, Conn's, and More
DJ
09/03Stocks to Watch: Alphabet, H&R Block, and Alexion Pharmaceuticals
DJ
09/01ALEXION PHARMACEUTICALS : Mike Page, Alexion Pharmaceuticals Invites You to SMi'..
AQ
08/30Alexion Down Over 11%, On Pace for Largest Percent Decrease Since December 20..
DJ
More news
Financials (USD)
Sales 2019 4 839 M
EBIT 2019 2 717 M
Net income 2019 1 907 M
Finance 2019 535 M
Yield 2019 -
P/E ratio 2019 12,8x
P/E ratio 2020 11,9x
EV / Sales2019 4,89x
EV / Sales2020 3,96x
Capitalization 24 178 M
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 155,48  $
Last Close Price 107,83  $
Spread / Highest target 70,6%
Spread / Average Target 44,2%
Spread / Lowest Target 12,2%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP, Head-Research & Development
Andreas Rummelt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS11.48%24 178
CSL LIMITED24.59%71 654
BIOGEN INC.-20.68%43 552
GRIFOLS17.77%17 681
SAMSUNG BIOLOGICS CO LTD--.--%16 399
BIOMARIN PHARMACEUTICAL INC.-11.92%13 318